Yu Weijie, Liu Ruixue, Miao Zhoulin, Zhang Liwei, Sheyhidin Ilyar, Ainiwaer Julaiti
Department of Cardio-Thoracic Surgery, The Fourth Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China.
Front Oncol. 2022 Oct 24;12:987704. doi: 10.3389/fonc.2022.987704. eCollection 2022.
Using blood-derived circular RNAs (circRNAs) may be an efficient tool for noninvasive fluid biopsy in diagnosing non-small cell lung cancer (NSCLC). However, no relevant systemic meta-analysis has been conducted so far to support the diagnostic value of using blood-derived circRNAs in NSCLC clinically. The aim of this study is to clarify the issue through a meta-analysis.
A systematic search strategy was used to search relevant literature in the databases of PubMed, Web of Science, and Cochrane Library from 2017 to 2022. The relationship between the diagnostic accuracy of circRNAs and NSCLC was analyzed. For the purpose of evaluating the quality of the literature, Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was used. Statistical analyses were assessed using Stata software (version 17.0) and META-DISC (version 1.4).
The meta-analysis included 1,093 patients with NSCLC and 959 controls. Results are as follows: pooled sensitivity, 0.78 (95% CI = 0.71-0.83, I = 71.86); pooled specificity, 0.76 (95% CI = 0.70-0.82, I = 70.12); pooled positive likelihood ratio (PLR), 3.3 (95% CI = 2.6-4.2, I = 37.56); pooled negative likelihood ratio (NLR), 0.29 (95% CI = 0.23-0.37, I = 64.67); diagnostic odds ratio (DOR), 11.42 (95% CI = 7.88-16.56, I = 99.05); area under the receiver operating characteristic curve (AUC), 0.84 (95% CI = 0.80-0.87). Based on the subgroup analysis, it appears that the heterogeneity is primarily caused by the NSCLC subgroup.
circRNAs are highly useful diagnostic biomarkers for NSCLC in China. Further prospective studies on the diagnostic value of circRNAs should be conducted in multiple countries.
https://www.crd.york.ac.uk/prospero/, identifier CRD42022323804.
利用血液来源的环状RNA（circRNA）可能是诊断非小细胞肺癌（NSCLC）的非侵入性液体活检的有效工具。然而，目前尚未进行相关的系统性荟萃分析来支持血液来源的circRNA在NSCLC临床诊断中的价值。本研究旨在通过荟萃分析阐明这一问题。
采用系统检索策略，在2017年至2022年期间检索PubMed、Web of Science和Cochrane图书馆数据库中的相关文献。分析circRNA的诊断准确性与NSCLC之间的关系。为评估文献质量，使用了诊断准确性研究质量评估-2（QUADAS-2）。使用Stata软件（版本17.0）和META-DISC（版本1.4）进行统计分析。
荟萃分析纳入了1093例NSCLC患者和959例对照。结果如下：合并敏感度为0.78（95%可信区间=0.71-0.83，I²=71.86）；合并特异度为0.76（95%可信区间=0.70-0.82，I²=70.12）；合并阳性似然比（PLR）为3.3（95%可信区间=2.6-4.2，I²=37.56）；合并阴性似然比（NLR）为0.29（95%可信区间=0.23-0.37，I²=64.67）；诊断比值比（DOR）为11.42（95%可信区间=7.88-16.56，I²=99.05）；受试者工作特征曲线下面积（AUC）为0.84（95%可信区间=0.80-0.87）。基于亚组分析，似乎异质性主要由NSCLC亚组引起。
circRNA是中国NSCLC非常有用的诊断生物标志物。应在多个国家对circRNA的诊断价值进行进一步的前瞻性研究。
